Articles & Video
Can payment models for gene therapies evolve fast enough to keep up?
HCEI and PIE: Is it time for pharma to be proactive in the argument over cost effectiveness?
"There is always something interesting behind a state's motivation to control prescription drug costs" - Q&A with Porzio Life Sciences
What does it mean to be patient centered in health economics?
Pricing & Reimbursement US 2020
programs are Medicare and Medicaid, under which plans are subject to detailed requirements set forth by statute or regulation.